Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | DRD4 | P21917 | 2/20 | 0.57 |
| ▸ | DRD3 | P35462 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 9/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12720773 | 0.86 | HTR1B (0.55) | HTR1BMEN1MAPK1KMT2AMAPT | |
| SCHEMBL3799623 | 0.83 | HTR1B (0.64) | HTR1BMEN1MAPK1KMT2AMAPT | |
| SCHEMBL15675622 | 0.83 | HTR1B (0.60) | HTR1BMEN1MAPK1KMT2AMAPT | |
| SCHEMBL4073823 | 0.83 | HTR1B (0.60) | HTR1BMEN1MAPK1KMT2AMAPT | |
| SCHEMBL1545429 | 0.83 | HTR1B (0.60) | HTR1BMEN1MAPK1KMT2AMAPT | |
| SCHEMBL7876385 | 0.81 | HTR1B (0.58) | HTR1BMEN1MAPK1KMT2AMAPT | |
| SCHEMBL10591827 | 0.81 | HTR1B (0.58) | HTR1BMEN1MAPK1KMT2AMAPT | |
| SCHEMBL11543577 | 0.81 | HTR1B (0.58) | HTR1BMEN1MAPK1KMT2AMAPT | |
| SCHEMBL3798923 | 0.81 | HTR1B (0.62) | HTR1BMEN1MAPK1KMT2AMAPT | |
| SCHEMBL7883052 | 0.80 | HTR1B (0.57) | HTR1BMEN1MAPK1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119219598-A | Cyclohexane derivative and medical application thereof | 上海京新生物医药有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-109563073-B | For the treatment of para-5-HT1AReceptor-controlled serotonergic disease-modulating compounds | 诺罗利西斯公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-3475268-B9 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2021-04-21 | — | — | EP | disclosed |
| EP-3475268-B1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2020-08-19 | — | — | EP | disclosed |
| US-10562853-B2 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors | NEUROLIXIS (FR) | 2020-02-18 | — | — | US | disclosed |
| US-20190194132-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2019-06-27 | — | — | US | disclosed |
| EP-3475268-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | Neurolixis (FR) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017220799-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2017-12-28 | — | — | WO | disclosed |
| EP-3260452-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | Neurolixis (FR) | 2017-12-27 | — | — | EP | disclosed |
| EP-2828238-B1 | SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES | ADAMED SP ZOO (PL) | 2016-05-25 | — | — | EP | disclosed |
| WO-2000058282-A2 | NOVEL [(2-SUBSTITUTED-5 -[3-THIENYL) -BENZYL]-[2- ([2-ISOPROPOXY-5-FLUORO] -PHENOXY) -ETHYL] -AMINE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | PIERRE FABRE MEDICAMENT (FR) | 2000-10-05 | — | — | WO | disclosed |
| US-6110956-A | ANTIDEPRESSANTS TREATING DISORDERS OF THE SEROTONIN-AFFECTED NEUROLOGICAL SYSTEMS | AMERICAN HOME PRODUCTS CORP. (US) | 2000-08-29 | — | — | US | disclosed |
| WO-2000032557-A1 | NOVEL 3-ALKOXYBENZYLAMINE DERIVATIVES AND THEIR USE AS MEDICINES FOR TREATING SCHIZOPHRENIA | PIERRE FABRE MEDICAMENT (FR) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999051576-A1 | N-ARYLOXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-10-14 | — | — | WO | disclosed |
| US-5958965-A | TREATMENT OF DISEASES ATTENDING DISTURBANCES IN THE SEROTINERGIC SYSTEMS, SUCH AS ANXIETY, STRESS, DEPRESSION, SEXUAL DYSFUNCTIONS AND SLEEP DISTURBANCES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-09-28 | — | — | US | disclosed |
| US-5958965-A | TREATMENT OF DISEASES ATTENDING DISTURBANCES IN THE SEROTINERGIC SYSTEMS, SUCH AS ANXIETY, STRESS, DEPRESSION, SEXUAL DYSFUNCTIONS AND SLEEP DISTURBANCES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0923548-A1 | 4-AMINOETHOXY INDOLES AS DOPAMIN D2 AGONISTS AND AS 5HT 1A? LIGANDS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998008817-A1 | 4-AMINOETHOXY INDOLES AS DOPAMIN D2 AGONISTS AND AS 5HT1A LIGANDS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-03-05 | — | — | WO | disclosed |
| US-3906000-A | Tricyclicazaindole derivatives | PFIZER | 1975-09-16 | — | — | US | disclosed |
| US-3898245-A | Tricyclicazaindole derivatives | PFIZER | 1975-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562853-B2 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors | HTR5A, HTR1A, HTR1E | HTR1B 12/4885MEN1 3695/4885MAPK1 2460/4885 |
| US-20190194132-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | HTR5A, HTR1A, HTR1E | HTR1B 12/4885MEN1 3695/4885MAPK1 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.